PSAFP refers to the abnormal rise of PSA in patients with advanced PCa after the start of second-line therapy (such as paclitaxel-based chemotherapy regimen and abiraterone endocrine therapy), which soon drops below the baseline level (28). The gene discussed is KLK3; the disease is posterior cortical atrophy.